Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 9, 2013, Pages 1507-1514

  Chan, Daniel ^a   Zheng, Yun ^b,e   Tyner, Jeffrey W ^c   Chng, Wee Joo ^a,d   Chien, Wen Wen ^d   Gery, Sigal ^b   Leong, Geraldine ^d   Braunstein, Glenn D ^b   Koeffler, H Phillip ^a,b,d  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Histone deacetylases; Novel therapeutic approach; Thyroid cancer; Tyrosine kinase inhibitors

Indexed keywords

BELINOSTAT; CYCLIN DEPENDENT KINASE INHIBITOR 1; DASATINIB; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PANOBINOSTAT; PAZOPANIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; THYROID CANCER; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ACETYLATION; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MICE; MICE, NUDE; SULFONAMIDES; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882584727     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1465-6     Document Type: Article

References (30)

1. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11(10):962-972. doi: 10.1016/S1470-2045(10)70203-5
2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784. doi: 10.1038/nrd2133 (Pubitemid 44348499)
3. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL (2010) Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95(6):2588-2595. doi: 10.1210/jc.2009-1923
4. Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, Ngan BD, Braunstein GD, Koeffler HP (2012) Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol Lett 3(4):807-815. doi: 10.3892/ol.2012.579
5. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, Wentworth J, Philips J, Clifton-Bligh R, Robinson BG (2003) Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88(1):354-357 (Pubitemid 36115188)
6. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26(29):4708-4713. doi: 10.1200/JCO.2007.15.9566
7. Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15(19):6232-6240. doi: 10.1158/1078-0432.CCR-09-0224
8. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5(10):981-989. doi: 10.1158/1541-7786.MCR-07-0324 (Pubitemid 350080267)
9. Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T (2007) Pathway mapping tools for analysis of high content data. Methods Mol Biol 356:319-350
10. Ellis L, Pili R (2010) Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3(8):2411-2469. doi: 10.3390/ph3082441
11. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12(15):4628-4635. doi: 10.1158/1078-0432.CCR-06- 0511 (Pubitemid 44297814)
12. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26(29):4714-4719. doi: 10.1200/JCO.2008.16.3279
13. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287):431-435. doi: 10.1038/nature08833
14. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15(12):4220-4227. doi: 10.1158/1078-0432.CCR- 08-2740
15. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW (2009) Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94(10):4107-4112. doi: 10.1210/jc.2009-0662
16. Licitra L, Locati LD, Greco A, Granata R, Bossi P (2010) Multikinase inhibitors in thyroid cancer. Eur J Cancer 46(6):1012-1018. doi: 10.1016/j.ejca.2010.01.010
17. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12(18):5570-5577. doi: 10.1158/1078-0432.CCR-06-0367 (Pubitemid 44497275)
18. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99(7):1492-1498. doi: 10.1111/j.1349-7006.2008.00837 (Pubitemid 351761743)
19. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104(12):1828-1835. doi: 10.1038/bjc.2011.156
20. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G (2010) Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 95(1):450-455. doi: 10.1210/jc.2009-0373
21. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12(5):1623-1629. doi: 10.1158/1078-0432.CCR-05-2378
22. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794-3801. doi: 10.1200/JCO.2008.18.7815
23. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93(11):4331-4341. doi: 10.1210/jc.2008-1102 (Pubitemid 352789529)
24. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR (2009) Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid 19(8):825-835. doi: 10.1089/thy.2008.0362
25. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31-42. doi: 10.1056/NEJMoa075853 (Pubitemid 351931094)
26. Smalley KS, Flaherty KT (2009) Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol 5(6):775-778. doi: 10.2217/fon.09.56
27. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16(1):17-44. doi: 10.1677/ERC-08-0154
28. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14(3):804-810. doi: 10.1158/1078-0432.CCR-07-1786 (Pubitemid 351231163)
29. Venugopal B, Evans TR (2011) Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18(11):1658-1671
30. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH (2009) Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94(1):164-170. doi: 10.1210/jc.2008-1631